One Week Comparison Study of PTH and PTHrP Infusions
Status:
Withdrawn
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
This is a dose escalation study to determine the maximum tolerable dose of Parathyroid
Hormone-related Protein, PTHrP, or Parathyroid Hormone, PTH, that can be given safely over
one week in healthy African-American volunteers. The investigators plan to infuse low doses
of intravenous PTHrP or PTH to determine if it leads to a sustained and progressive
suppression of bone formation as occurs in humoral hypercalcemia of malignancy (HHM) or an
increase in bone formation as occurs in hyperparathyroidism (HPT). Additionally, the
investigators will assess the direct influence of PTHrP and PTH on vitamin D metabolism,
markers of bone turnover, and fractional excretion of calcium. These results will be compared
to previous studies of Caucasian volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
University of Pittsburgh
Treatments:
Anabolic Agents Hormones Parathyroid Hormone Parathyroid Hormone-Related Protein Testosterone Congeners